Buprenorphine
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Buprenorphine is a semi-synthetic opioid of the orvinol class. It is structurally related to morphine but only partially activates opioid receptors rather than fully switching them on. This partial activation suppresses pain while placing a ceiling on both euphoria and dangerous breathing slowdown.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized from thebaine at a UK pharmaceutical laboratory in the late 1960s, buprenorphine was developed in a search for safer analgesics.[1] It first reached patients as an injectable painkiller in 1978, then repositioned as an opioid dependence treatment after FDA approval in 2002.[1] It is now one of the most widely prescribed medications for opioid dependence worldwide.
Subjective effects include pain suppression, sedation, reduced anxiety, quiet warmth, and muted euphoria. The experience is defined by a ceiling — physical discomfort and emotional tension recede into a calm that plateaus rather than deepening, with an anxiolytic quality distinct from classical opioid reward.[2][3][4] Nausea, constipation, mental slowing, and pupil constriction are characteristic unwanted effects.
Buprenorphine produces moderate physical dependence, with a wider safety margin than full-agonist opioids.[5] That margin disappears with benzodiazepines, which deepen respiratory depression beyond what buprenorphine alone can cause — this combination accounts for most buprenorphine fatalities.[6] Decades of clinical use and controlled trials provide a substantial evidence base, though a human lethal dose has never been formally established.
History[edit]
Discovery
Buprenorphine was synthesized from thebaine at Reckitt & Colman in the United Kingdom, developed by Kenneth W. Bentley and David G. Hardy between approximately 1966 and 1969.[1][2][7] Early testing revealed analgesic potency 25–40 times that of morphine[2] alongside an unusual ceiling on respiratory depression. Martin and colleagues confirmed its partial agonist character in 1976,[7] establishing the concept that would define its clinical identity.
Clinical adoption
Buprenorphine first reached patients in 1978 as an injectable analgesic in the UK (Temgesic), followed by a sublingual form around 1982 and US injectable approval (Buprenex) in 1985.[8] France's 1996 rollout of high-dose sublingual buprenorphine (Subutex) for opioid dependence showed clear mortality benefits but also revealed lethal risk when injected alongside benzodiazepines.[6] The United Nations placed buprenorphine in Schedule III of the Convention on Psychotropic Substances in 1989.[9]
Modern era
FDA approval of Subutex and Suboxone (buprenorphine/naloxone) in October 2002 made buprenorphine the first opioid dependence medication a physician could prescribe from a standard office.[1] Long-acting formulations followed — a six-month subdermal implant in 2016 and a monthly injectable in 2017 — addressing adherence. The December 2022 elimination of the US X-waiver removed the last major prescribing barrier, and research into antidepressant applications continues.[10][9]
Chemistry[edit]
Structural class
Buprenorphine belongs to the orvinol subclass of morphinans — semi-synthetic opioids built from thebaine, an alkaloid of the opium poppy.[11][2][7] Its molecular formula is C₂₉H₄₁NO₄ (467.6 g/mol). A cyclopropylmethyl group at the nitrogen position is what makes it a partial agonist — the single structural feature responsible for the ceiling effect that distinguishes it from full-agonist opioids like the closely related orvinol etorphine.
Physical properties
The free base is a white crystalline powder; the hydrochloride salt is used in most clinical formulations. Buprenorphine is approximately 96% protein-bound in plasma.citation needed
Pharmacology[edit]
Mechanism of action
Buprenorphine acts on opioid receptors in several ways simultaneously. At µ-opioid receptors, it binds with extremely high affinity and dissociates very slowly.[11][2] This creates a ceiling on respiratory depression — but not on pain suppression, which continues to increase with dose.[7][6][12]
At kappa-opioid receptors, buprenorphine acts as a partial agonist, reducing stress-related dysphoria and contributing anxiolytic effects.[2][3][4] At delta-opioid receptors it is an antagonist,[2] and at nociceptin receptors an agonist.[11] At maintenance doses, high receptor occupancy blocks the effects of additional full-agonist opioids.[13][14]
Pharmacokinetics
Sublingual bioavailability averages ~51%, with peak levels at 40–80 minutes and a half-life of 24–42 hours.[15][16] Oral swallowing yields ~3% bioavailability due to heavy liver metabolism.[17] The primary metabolite, norbuprenorphine, is itself a breathing suppressant whose plasma levels can match or exceed the parent compound.[18][19] Strong CYP3A4 inhibitors substantially increase buprenorphine exposure.[20]
Neuroscience[edit]
Where it acts
Buprenorphine's rewarding effects originate in the brain's dopamine pathway. Partial opioid receptor activation in the midbrain releases dopamine into the brain's reward center — but to a lesser degree than full agonists like morphine or heroin.[7][13] This muted dopamine release explains buprenorphine's attenuated euphoric ceiling and lower addiction liability.
Why it matters
For people with opioid dependence, buprenorphine stabilizes a brain that chronic opioid use has disrupted. Chronic use recruits stress hormones and other anti-reward signals that drive negative affect during withdrawal. Buprenorphine maintenance holds that state steady — partial opioid receptor activation prevents withdrawal-driven distress, while κ-opioid modulation directly counteracts the dysphoric signal.[2][3][4]
Several questions about buprenorphine remain unanswered. Why does engaging a truncated receptor variant produce pain suppression without proportional respiratory depression? When does norbuprenorphine — the full-agonist metabolite — accumulate enough to override the parent drug's ceiling? Does long-term maintenance produce brain changes distinct from those seen with full-agonist opioids[21]?
Subjective Effects[edit]
The buprenorphine experience is defined by a ceiling. Physical pain recedes, emotional tension softens, and a quiet warmth sets in — and then it stops deepening. Where full-agonist opioids escalate with dose, buprenorphine plateaus into a sustained, ceiling-limited calm.
Relative to its class, buprenorphine sits well below morphine, oxycodone, or methadone in terms of euphoria and reward. The closest comparison is a low-dose morphine experience that holds steady rather than climbing — more rewarding than naltrexone, but substantially blunted by comparison.
Effect Grid
At common sublingual doses (2–8 mg), the full spectrum of buprenorphine's opioid effects manifests. Analgesia is pronounced and reliable. Sedation deepens to a comfortable drowsiness. Euphoria is present but distinctly attenuated compared to full agonists — a warm, enveloping contentment rather than intense reward. Anxiolysis is substantial. Cognitive euphoria and emotional blunting emerge.
Physically, nausea is more common (especially in opioid-naive individuals), along with constipation, miosis, mild respiratory depression (within ceiling limits), and pruritus. Sweating may occur.
Pharmacodynamic effects persist 18–24 hours from a single sublingual dose. Sleep is often deepened. Functional impairment is moderate — driving and operating machinery are unsafe during this period.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Visual haze / noise · Visual processing suppression · Internal hallucinations
Body high · Sedation · Nausea · Bodily heaviness · Muscle relaxation · Physical fatigue · Tactile euphoria · Spontaneous body sensations · Dizziness · Sexual arousal suppression · Appetite suppression · Excessive sweating · Dry mouth · Vomiting · Breathing alteration · Headache · Insomnia · Tingling / electric sensations · Respiratory depression · Heart rate perception changes · Abnormal heartbeat · Involuntary body movements · Nystagmus (eye wobbles) · Pain enhancement · Bodily dissociation
Bodily heaviness · Muscle relaxation · Physical fatigue · Tactile euphoria · Spontaneous body sensations · Dizziness · Sexual arousal suppression · Appetite suppression · Excessive sweating · Dry mouth · Vomiting · Breathing alteration · Headache · Insomnia · Tingling / electric sensations · Heart rate perception changes · Abnormal heartbeat · Involuntary body movements · Nystagmus (eye wobbles) · Pain enhancement · Bodily dissociation
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Motivation suppression · Memory suppression · Cognitive dysphoria · Confusion · Language suppression · Memory fragmentation · Thought disorganization
Motivation suppression · Memory suppression · Cognitive dysphoria · Confusion · Language suppression · Memory fragmentation · Thought disorganization
Anxiety · Irritability · Dysphoria
Disinhibition · Social disconnection · Sociability enhancement · Cognitive disconnection
Timeline
First effects emerge faster than sublingual due to nasal mucosal absorption. Warmth and mood shift detectable within 10–30 minutes.
More rapid buildup than sublingual route. Opioid effects intensify quickly — analgesia, sedation, and euphoria build to noticeable levels. Higher reported abuse liability via this route reflects the faster onset kinetics.
Peak intensity reached earlier and potentially felt as more acute than sublingual, though the partial agonist ceiling still limits maximum effect. Nausea, sedation, and euphoria peak during this window.
Sustained moderate effects. Duration is shorter than sublingual plateau due to different absorption kinetics, but receptor binding still drives prolonged action.
Gradual decline toward baseline. Residual sedation and mild analgesia persist.
Residual effects from the long elimination half-life. Mild mood changes and physical residue may persist for 12–48 hours.
⚠ Do not drive or operate machinery until all sedation and psychomotor slowing have resolved — wait at minimum 12 hours after last noticeable effects.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- opioids
Toxicity
Acute toxicity
Buprenorphine's partial agonist ceiling limits respiratory depression at supratherapeutic doses when taken alone.[6][7] Fatal overdose from buprenorphine alone is rare — forensic data confirmed this pattern.[22]
Standard naloxone doses may not reliably reverse buprenorphine-induced respiratory depression due to its extremely strong receptor binding. High-dose or repeated naloxone administration may be required. Respiratory support is the critical intervention in suspected overdose.[6]
Heart and circulation
Buprenorphine has a favorable cardiac safety profile. Controlled trials showed no clinically significant effects on heart rhythm at therapeutic and supratherapeutic doses,[23] and adverse event rates for irregular heartbeat are substantially lower than for methadone.[24][25]
Liver toxicity
At standard clinical doses, liver damage risk appears low.[26] Animal studies showed dose-dependent liver damage at high doses.[27]
Polysubstance toxicity
Combining buprenorphine with benzodiazepines is the most dangerous interaction. Benzodiazepines boost the brain's inhibitory signaling, deepening breathing suppression beyond buprenorphine's partial-agonist ceiling. In animal models, benzodiazepine pretreatment reduced buprenorphine's lethal dose approximately 6-fold.[5] Multiple fatalities involving intravenous buprenorphine combined with benzodiazepines were documented in France after the 1996 Subutex rollout.[6] The interaction is pharmacodynamic — not primarily a drug-level effect.[28]
Concurrent benzodiazepine use among buprenorphine patients causes excess sedation leading to respiratory depression and death.[29][30]
Psychological risks
The primary acute psychological risk is precipitated withdrawal — giving buprenorphine to someone with active full-agonist opioid saturation triggers rapid-onset withdrawal: intense anxiety, dysphoria, restlessness, and autonomic instability.[31] Cognitive slowing and sedation occur in a dose-dependent manner but reach a ceiling consistent with partial agonism.
Depressive symptoms may emerge during withdrawal from chronic use, as removal of κ-opioid modulation allows stress-related dysphoria to resurface.
Tolerance and dependence
Tolerance develops to analgesia, sedation, euphoria, and respiratory depression with prolonged use.[7] The partial-agonist ceiling persists even in tolerant individuals. Cross-tolerance to other opioids is incomplete — buprenorphine-maintained patients still show residual effects from full-agonist challenge doses.[13]
Physical dependence develops at moderate intensity. Withdrawal is milder but more protracted than full-agonist opioid withdrawal:
- Onset: 24–72 hours after last sublingual dose
- Duration: Weeks to months; injectable formulations may extend this further[32]
- Symptoms: insomnia, muscle aching, anxiety, restlessness, gastrointestinal disturbance, sweating — milder than Methadone or morphine withdrawal
Addiction liability is lower than full-agonist opioids due to the ceiling on euphoria.[7][13]
Drug interactions
CNS depressant synergy
Benzodiazepines represent the highest-risk combination, supported by human fatality data and animal lethality studies.[6][5][30] Benzodiazepines potentiate the brain's inhibitory signaling system, deepening breathing suppression beyond the partial-agonist ceiling.
Alcohol and GHB/GBL carry lethal risk through the same mechanism.safety citation needed
Opioid interactions
Buprenorphine's stronger receptor binding displaces full-agonist opioids, triggering acute withdrawal in dependent individuals.[31] Full agonists taken during buprenorphine maintenance produce attenuated effects because receptors are already occupied.[13]
Tramadol combined with buprenorphine risks cumulative breathing suppression and a potential serotonin-related reaction.safety citation needed
Pharmacokinetic interactions
CYP3A4 inhibitors — including certain antifungals (voriconazole, ketoconazole) and HIV medications (ritonavir) — substantially increase buprenorphine blood levels, potentially causing excess opioid effects.[20]
CYP3A4 inducers (rifampin, carbamazepine) are expected to reduce buprenorphine levels, potentially causing breakthrough withdrawal in maintenance patients.citation needed
Contraindications
- Concurrent benzodiazepines or CNS depressants — unsupervised combination is dangerous; clinical co-prescribing requires risk management protocols[6]
- Recent full-agonist opioid use — precipitated withdrawal risk requires adequate washout time or microinduction protocols[31]
- Acute severe breathing difficulty — buprenorphine adds respiratory depression even if limited by its ceiling
- Severe liver impairment — affects metabolism of both buprenorphine and naloxone in combination products; dose adjustment may be required
- Concurrent MAO inhibitor use — risk of serotonergic and adrenergic crisiscitation needed
- Pregnancy — not an absolute contraindication, but requires specialist management due to altered metabolism[19]
Harm Reduction[edit]
Forms & Identification
Buprenorphine circulates primarily as pharmaceutical products — sublingual tablets, films, and transdermal patches. Diversion of pharmaceutical products and counterfeit tablets have been documented. Reagent kits can confirm an opioid is present but cannot identify buprenorphine specifically; imprint codes and manufacturer packaging are the primary verification method.
Film formulations dissolve sublingually and should not be swallowed — oral bioavailability is negligible. Tablets crushed for insufflation increase abuse liability and introduce unpredictable dosing.[33][34]
Guidelines
- Verify unfamiliar tablets or films using imprint code identification before use
- Start with lower doses when tolerance is uncertain — buprenorphine's long half-life means effects accumulate
- Do not transition directly from a full-agonist opioid to buprenorphine without adequate washout time; precipitated withdrawal is severe and immediate
- Ensure someone is aware of use and can check in, particularly with a new source or changed dose
- Avoid redosing within the first 2–3 hours — sublingual absorption is slow and peak effects are delayed
- Keep naloxone available, noting that higher-than-standard doses may be needed to reverse buprenorphine effects
Set & Setting
Buprenorphine's long duration and slow onset make the immediate environment less acutely critical than with fast-acting opioids. Psychological context still shapes the experience — in a treatment context, a stable, low-stress environment supports adherence. For non-medical use, the extended duration means effects persist well beyond what those accustomed to shorter-acting opioids may expect.
Aftercare & integration. Post-use recovery is shaped by buprenorphine's long half-life — residual sedation and cognitive dulling may persist for 24 hours or more. Sleep, hydration, and light nutrition support physical recovery. Constipation may require attention for several days.
For those discontinuing maintenance treatment, the extended withdrawal timeline — weeks to months — benefits from structured support. Gradual tapering under medical supervision is preferred over abrupt cessation. Psychological support during tapering addresses the anxiety and low mood that accompany protracted withdrawal.
Recovery & Support
Buprenorphine is both a substance of dependence and a primary tool for treating opioid dependence. For those seeking to discontinue buprenorphine itself, a slow medical taper is the most supported approach — withdrawal is milder than from full agonists but more protracted.[7]
Peer support programs, including SMART Recovery and mutual aid groups, provide community structure during and after tapering. Medical providers experienced in opioid use disorder can guide individualized taper schedules and address the psychological dimensions of recovery. Returning to buprenorphine maintenance after instability is an evidence-supported decision, not a failure.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Dangerously slow or stopped breathing, blue or grey lips and fingertips, inability to be roused, gurgling or choking sounds, extreme unresponsiveness. These signal respiratory depression — buprenorphine's ceiling makes this rare when used alone, but the ceiling is abolished by benzodiazepines or alcohol.
Immediate steps:
- 1. Call emergency services immediately if breathing is slow, irregular, or absent
- 2. Administer naloxone if available — higher than standard doses may be required due to buprenorphine's strong receptor binding[6]
- 3. Place the person in the recovery position (on their side) to prevent choking
- 4. Perform rescue breathing if trained and breathing has stopped
- 5. Do not leave the person alone; do not induce vomiting
What to tell the dispatcher: Name the substance (buprenorphine), estimated amount and time taken, any other substances involved (especially benzodiazepines or alcohol), and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Naloxone is the standard opioid reversal agent but may be less effective against buprenorphine than against full-agonist opioids due to its high receptor affinity. Repeated doses or continuous infusion may be necessary. Respiratory support — maintaining the airway and providing rescue breathing — is the critical intervention.[6]
Legal Status[edit]
Buprenorphine is internationally controlled as an opioid with recognized medical uses, placed in Schedule III of the UN Convention on Psychotropic Substances in 1989.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule III (Controlled Substances Act) | Rescheduled from Schedule V to Schedule III in October 2002. X-waiver eliminated December 2022; all Schedule III practitioners may prescribe for opioid use disorder without patient limits[9] |
| United Kingdom | Class C, Schedule 3 (Misuse of Drugs Act 1971) | Possession without prescription: maximum 2 years imprisonment. Supply: maximum 14 years imprisonment[9] |
| Australia | Schedule 8 (Controlled Drug) | Requires specific permit or authorization[9] |
| Canada | Narcotic (Controlled Drugs and Substances Act) | Listed as a narcotic under the CDSA. Unlike methadone, does not require Section 56 exemption for prescribing[9] |
| European Union | Prescription-only (varies by member state) | Generally controlled as an opioid; specific scheduling varies by member state |
| United Nations | Schedule III (Convention on Psychotropic Substances) | Placed in Schedule III in 1989 following WHO recommendation[9] |
Legal status varies by jurisdiction and changes over time. This information is not legal advice.
references
- [1] ^abcdHeidbreder C, Fudala PJ, Greenwald MK (2023) History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder — Drug and Alcohol Dependence Reports doi:10.1016/j.dadr.2023.100133
- [2]
- [3] ^abcRobinson SA, Erickson RL, Browne CA, Lucki I (2017) A role for the mu opioid receptor in the antidepressant effects of buprenorphine — Behavioural Brain Research doi:10.1016/j.bbr.2016.10.050
- [4] ^abcStefanowski B, Antosik-Wojcinska A, Swiecicki L (2020) The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies — Psychiatria Polska doi:10.12740/pp/102658
- [5] ^abcBorron SW, Monier C, Risede P, Baud FJ (2002) Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat — Human and Experimental Toxicology PMID:12507255
- [6]